Congenital or acquiredsyphilis is the cause ofMeniere' s disease in six percent of all cases. The pathogenesis is endolymphatic hydrops and osteitis of the otic capsule which produces the characteristic fluctuating hearing loss, tinnitus and ear pressure associated with episodic spells ofvertigo. The ear symptoms are, at first, typical of Meniere's disease ofother etiologies. Failure to establish the specific etiologic diagnosis can result in unnecessary surgical treatment or inappropriate medical therapy. In some cases, ifa steroid, the specific treatment, is not given promptly, hearing can be quickly and permanently lost. The etiology is confirmed by obtaining a reactive fluorescent treponema antibody absorption (FTA-abs) test. The clinicalfeatures and natural history ofMeniere's disease of syphilitic etiology are unique. Ear symptoms often begin in the fifth decade oflife, first in one ear and, after a few years, involving the second ear. Reduced or absent caloric responses are characteristic. When hearing loss is severe and sudden, this condition represents a true medical emergency and should be treated with prompt administration of steroids. An endolymphatic subarachnoid shunt operation is occasionally necessary as adjunctive management. An analysis of 34 cases shows that long-term use of steroids can maintain effective hearing for more than 20 yeurs.
Introduction
Meniere's disease caused by congenital or acquired syphilis is initially clinically indistinguishable from Meniere's disease of other etiologies. After a diagnosis of Meniere's disease is confirmed, the syphilitic etiology is established by obtaining a reactive fluorescent treponema antibody absorption (FTA-abs) test. Treatment involves prompt and long-term administration of prednisone. The clinical features and natural history of Meniere's disease of syphilitic etiology are unique. Ear symptoms often begin in the fifth decade of life, first in one ear and, after a few years, involving the second ear. When hearing loss is severe and sudden, this condition represents a true medical emergency and treatment consists of the prompt administration of steroids. Previous papers have dealt with short-term follow-up. The purpose of this paper is to review the clinical features of Meniere's disease due to syphilis and to report on follow-up as long as 27 years to show that long-term preservation of hearing can be achieved.
Literature
Ear symptoms have been known to be caused by syphilis since ancient times. In 1964, Collart' showed that live spirochetes resistant to all forms of antibiotic therapy could coexist with their hosts in late syphilis ( Figure I ). Before that time, patients with congenital syphilis and who had positive results to non-specific tests for syphilis were called Wassermann Fast. The author, in 1972, first recommended that the specific and sensitive reactive fluorescent treponema antibody absorption (FfA-abs) test be performed on all Meniere's patients to establish the etiology of syphilis." It was commonly noted that the patient would have a non-reactive VDRL or other nonspecific tests for syphilis, and that for that reason other tests should be abandoned in favor of the FfA-abs test. In a study of 120 patients with Meniere's disease, 7% of the cases were found to be caused by syphilis. This incidence was later refined to 6%.3 A method of treatment was recommended which involved hospitalization and administration of penicillin, 20-million units intravenously daily for seven days, in order to eliminate the risk of overlooking a treatable syphilis condition. During the same hospitalization, the patient is placed on prednisone 10mg four times daily and subsequently maintained on the lowest dose of steroids that will maintain hearing. Patterson, in 1967 , reported four cases of syphilitic Meniere's disease treated with prednisone." His longest follow-up was 19 months. He suggested that long-term steroid therapy for congenita11uetic hearing loss offered some hope of improving and stabilizing hearing and preventing progression to what otherwise inevitably becomes a profound handicapping deficit. Hendershot, in 1973 , also recommended treatment with prednisone but suggested an intermittent dosage every other day.' Shambaugh," and Linthicum and El-Rahman? have demonstrated that the endo1ymphatic duct can be obstructed by a syphilitic gumma. Physical obstruction of the endolymphatic duct or entrance to the sac by a gumma or by any other cause will obviously prevent any shunt procedure of the endolymphatic sac from being a success. The author, in 1969 10 and 1970,11 recommended that the en-do1ymphatic subarachnoid shunt procedure be performed on patients with syphilitic Meniere's disease who require more than 20 mg of prednisone daily to control their symptoms. Paparella et al, 12in 1980, reported good results from sac decompression for refractory luetic vertigo in eight patients. The results of electrocochleography in patients with syphilis and hearing loss were first reported by Ramsden et al in 1977 . 13 They discussed the detection of endolymphatic hydrops and differences between the ECoG of patients with syphilis where few hair cells remained with those with Meniere's disease of other causes where a large number of hair cells were retained. A unique characteristic of syphilitic Meniere's disease is bilateral markedly reduced caloric vestibular responses. This finding was reported by the author in 1972 2 and examined in detail by Wilson and Zoller" in 1981. Otologic involvement in late syphilis in a study of patients seen at the Mayo Clinic was reported by Steckelberg and McDonald in 1984 . 15 They reviewed the records of 38 patients seen from 1970 to 1979; 24% had tinnitus, hearing loss and vertigo, typical of Meniere's disease. Another 12 of 15 patients who had congenital syphilis had one or more stigmata, of which interstitial keratitis was the most common, appearing in 11 of 15. "Hutchinson's teeth" was seen in four patients, frontal bossing, high palatal arch and nasal deformity were present in two patients, and "saber shins" and "mulberry molars" were each present in one. They felt that a diagnosis of endolymphatic hydrops could be made in only nine patients (24%).
The routine evaluation of all patients with Meniere's disease was recommended by the author in 1972. 2 The 510 details of this recommendation were discussed extensively by Hughes and Rutherford in 1986. 16 
Materials and Methods
From 1964 through 1992 the author diagnosed and treated 34 patients with Meniere's disease and syphilis. All had a complete neurotologic examination and stateof-the-art testing available at the time of their examination. In all cases, audiometry for pure tones and speech, short-increment sensitivity index (SISI), Bekesy audiometry and impedance audiometry were performed. All had vestibular tests with electronystagmography for spontaneous positional and bitherma1 caloric-induced nystagmus. Plain petrous pyramid x-rays for Towne, Caldwell and Stenver's views and routine blood tests were performed. The VORL test was performed until 1966, at which time all patients were given the FTA-abs test. After 1969, routine blood tests included viral studies including T-3, T-4, and thyroxine tests (Murphy and Patee method). Also added at this time were the five-hour glucose tolerance test, allergy evaluation, test for adrenal and pituitary function when indicated, psychological testing, viral study and polytomography of the otic and peri-otic ducts. Electrocochleography was added in 1971 and lipoprotein phenotype examination in 1974. In 1981, sinusoidal harmonic acceleration, computerized ocular tracking and simultaneous bilateral bithermal caloric tests were initiated. Early and middle latency brainstern evoked response audiometry became routine in 1977, and electrically-evoked response brainstem audiometry was begun on a research basis in 1985. Magnetic resonance imaging and vestibular auto rotation testing have been performed since 1986.
Diagnostic Criteria and Examination
The diagnosis of Meniere's disease was established in patients with a history of recurrent episodic vertigo characteristically lasting from 30 minutes to three hours, associated with progressive low-tone hearing loss and low-pitched tinnitus which often build up gradually to an attack of rotary vertigo and subside when the vertigo has stopped. Nystagmus is common during the vertigo attack. Spells of vertigo mayor may not be associated with violent nausea, vomiting and retching. Between spells, the patient, early in the course of the disease, may be free from all symptoms; later in the course of the disease he may experience differing degrees of constant instability. Endo1ymphatic hydrops is confirmed by the presence of recruitment, distortion of hearing, diplacusis and a characteristic e1ectrocochleogram. Brainstem audiometry, blood tests and imaging rule out other conditions such as acoustic neuroma, hyperlipidemia and diabetes. hearing loss. Most patients will not admit that they have had acquired syphilis, nor will they know that they might have congenital syphilis. For this reason it is best in most cases to avoid questioning the patient about this until a positive Fl'A-abs test has been obtained on three different occasions. There are clues that will help the otologist to suspect the diagnosis. Other stigmata ofcongenital syphilis such as "notched teeth" may be the first clue. Since the majority of patients with congenital syphilis develop ear symptoms on one side at age 42 or 43, and in the opposite ear at age 46, the age and sequence can provide a clue if the patient is first seen when the second ear becomes involved. With bilateral involvement many patients who have Meniere's disease of syphilitic etiology will demonstrate markedly hypoactive caloric responses. Therefore, a 46-year-old patient first seen with bilateral Meniere's disease and absent caloric responses bilaterally is very Iikley to ha ve congenital syphilis as the cause.
Elents
Becau se of the social implic ations, I find it best to repeat any positive FfA-abs test two times before confronting the patient with the result s. At the time the patient is informed of the test and its meaning, the patient is asked whether or not the diagnosis had been made before, whether the condition was acquired or whether there had been any previous treatment. Ifthe answer is positive, a diagnosis of acquired syphilis can be established and treatment with penicillin can eradicate the spirochetes. If there is no history of acquired syphilis, the possibility of congenital syphilis is explored. Often, an elderly parent will admit to having had syphilis treated before the birth of their child and the etiology of congenital syphilis is confirmed. In all cases of congenital and acquired syphilis, follow-up testing of appropriate family members should be conducted including parents, siblings, spouse and children.
It is desirable to have a knowledgeable ophthalmologist perform an examination for interstitial keratitis and provide any long-term follow-up treatment which may be necessary for the eyes. The author first became aware of the value of the Fl'A-abs test by sharing a program with a visiting ophthalmologist who was an expert in congenital syphilis of the eye and who used the FfA-abs test early in the course of its development. It is important to understand that the object of this paper is not and is in no way involved with tertiary syphilis. These patients never have tabes dorsalis nor paresis and there is no value in perform-512 ing a spinal tap on them other than for investigational purposes. These patients never have involvement of any organ system other than the inner ear and the eye . Patients who have early or secondary acquired syphilis can usually be cured with intensive antibiotic treatment. There is no known treatment today that will eradicate the live spirochetes living in a symbiotic relationship with the patient who has Meniere's disease of congenital syphilitic etiology . These patients are not infectious and do not require public health contact tracking.
Treatment
When the diagnosis has been established, a specific treatment is indicated. The patient is placed in the hospital for seven days for three purposes: I) Crystallin penicillin 20 million units is given every 24 hours intravenously for se ven days. This provides a more than adequate attempt at eradicating any treatable acquired syphilis. 2) Prednisone 10 mg is administered orally every six hours in an effort to increase hearing to its best level. Sedatives can be given if this dosage produces hyperactivity, psychosis or insomnia . Regular pure-tone and speech audiometry is performed and the steroid dosage is reduced progressively to 5 mg qid within one month. Ifhearing remains stable, it is then more slowly reduced to the minimum level that will reta in stable, good hearing. If the hearing cannot be changed with steroids they are gradually discontinued. 3) A thorough examination is performed by an internist to identify any problem such as diabetes, duodenal ulcer, tuberculosis or psychosis. Ideally, this same internist will be involved in long-term follow-up of the patient with respect to efforts to detect, avoid and treat the side effects of long-term steroid use. The expected side effects involve the development of diabetes mellitus, obesity, fluid retention, bleeding, duodenal ulcers, hemorrhagic skin lesion s, psychosis and osteoporosis with frequent multiple fractures. Long-term care involves treatment with diuretics, a reduction diet, antacids and methods to tolerate fractured bones. It is important to emphatically inform the patient and family that prompt, sudden, permanent hearing loss may result if the necessary steroid is withdrawn at any time in the future. Because of the long-term nature (more than 20 years) of the course of this disease, it is likely that the patient may see another physician who might treat a complication many years in the future. This physician, unaware of the implications, must be informed by the patient of the risks of withdrawing medication. I advise these patients to have their physicians immediately call me or another otologist knowledgeable about Meniere's disease of syphilitic etiology. Should a lifethreatening situation exist, a decision might be made to discontinue the steroid and accept permanent deafness. In 
Results
Thirty-four patients with Meniere's disease were found to have a positive FfA-abs test for syphilis. The disease was found to be acquired in two men and was eradicated with antibiotic treatment. Their hearing has remained stable. The condition was congenital in 32 patients, 12 men and 19 women whose ages ranged from 16 to 58 years . Of this group, only one child, a girl aged 16, was seen . The 16-year-old girl was found to be rapidly losing her hearing and had parents and siblings with the same condition. The family refused treatment and was lost to follow-up. In four cases , (two men and two women ), the ear involvement remained unilateral for more than to years and it seemed likely that they, in fact, had unilateral idiopathic Meniere's disease coincident with congenital syphilis. In other words, although they had both condi-
with useful hearing being maintained on 5 to 20 mg daily in divided doses. Four patients have been followed for more than 20 years (Table I) . Of these 18 patients, eight had have unilateral endolymphatic subarachnoid shunts and four have had bilateral endolymphatic subarachnoid shunts to reduce the amount of steroid required and to help .control their symptoms. Two patients developed fistulae. A 35-year-old Caucasian man with bilateral Meniere's disease of syphilitic etiology of four years' duration had a return to normal hearing on both sides with treatment. He had been given prednisone 5 mg four times daily, ampicillin 500 mg four times daily and Benemid 500 mg four times daily continuously for four months, at which time a spinal tap was performed and viable spirochetes were identified in the spinal fluid ( Figure 1 ). One ml of this spinal fluid was at the same time injected into the testes of each of two white rabbits. After six months, both rabbits developed positive FTA-abs tests, the first known transfer of infection of this type. The rabbits were then sent to the communicable disease center for further follow-up examination. Because of the finding of spiro-chetes in this patient's spinal fluid, he agreed to undergo aspiration of perilymph through a hole in the footplate, as described by Silverstein," in order to search for spirochetes within the perilymph. None were found in this case in 1966. It is of interest, however, that the III 0 ml hole placed in the center of the footplate, which had been covered with Gelfoam, failed to heal, apparently because of the continued administration of prednisone 20 mg daily. Hearing was fluctuant and associated with intermittent vertigo. Exploratory tympanotomy two months later revealed an unhealed perforation within the footplate with perilymph fistula, The area was scarified and covered with fascia. Symptoms promptly subsided and hearing returned to normal.
A 50-year-old woman had a left endolymphatic subarachnoid shunt operation as an adjunct to reducing steroid treatment in 1971. Her hearing remained in the normal range with the maintenance dose of prednisone 15 mg four times daily. In 1981, 10 years later, she suddenly developed a watery discharge that dripped from the left side of her nose when she placed her head forward. Pro mpt exploration of the left mastoid ectom y with a local anesthetic revealed an opening 4 mm long through the dura and the arachnoid at the inferior edge of the endolymphatic sac. There was no inflammation nor obviou s reason for the de velopment of this opening. It was not involved with the sac nor the endolymphatic subarachnoid shunt tube. A piece of temporal is muscle was placed throu gh the opening to act as a stopper. She has had no further leakage. The opening appeared in an area of dura which may have been naturally thin. Bone had been removed from it at the previ ous shunt operation and it is possible that the longterm chronic use of prednisone contributed to the spontaneous development of this fistula. She has had no further problems with cerebrospinal fluid leakage.
Case Reports Case 1
A 35-year-old woman was diagnosed by her county health department as hav ing congenital syphilis at age 20. Blood serology was 4+. The re was no history nor evidence of interstitial keratitis. Between December of 1949 and December 1956 the patient received a total 40,200,000 units of pen icillin. In 1962, at the age of 32, she began to develop otologic symptoms with positional vertigo lasting for three month s. The vertigo subsided but she continued to have premenstrual left tinnitus and hearing loss. She was first seen by the author on 7-9-65 at which time she was asymptomatic (Fig ure 2) . She was placed on vasodilators. Three month s later she returned with a progressive left hear ing loss. Predni sone therapy was initiated and within five month s the left ear had stabilized with a left pure-tone threshold level of 52 dB and 84% discrimination. The right ear had returned to normal. Hearing remained stable for 19 months on 2.5 mg prednisone daily. In 1970, she completely lost hearing in her right ear for 24 hours. Despite predni sone treatment she co ntinued to have major fluctu ations in her hearing on both sides . In 1971, hearin g was totally lost on the left side. Predni sone was increased to 10 mg four times daily. during the previous year. Within nine months hearing dropped to a profound level with no speech discrimination despite 22.5 mg prednisone daily and vasodilating medications. On 5-4-78 a right endolymphatic subarachnoid shunt operation was performed. Postoperatively hearing improved by 10 dB but speech discrimination did not return (Figure 4 ). Follow-up on 4-14-92 revealed that she had no vertigo, no tinnitus and no word comprehension, although she continues to use a right hearing aid. She is a cochlear implant candidate. Comment: This patient was initially reported by Patterson as his Case No. 2. 6 In the short-term she did reasonably well and remained stable as his short-term report indicates. A 27-year follow-up in her case shows that she maintained useful hearing for 22 years before developing a total loss. In retrospect, it may have been desirable early in the course of the disease to perform an endolymphatic subarachnoid shunt operation in each ear and to maintain a higher daily dose of steroids. The shunt procedure on the right ear was performed too late to restore hearing.
Case 2
A 47-year-old Caucasian woman was seen on 10-9-69 with a two-month history of left fluctuating hearing, tinnitus, ear pressure and episodic vertigo. Audiometry demonstrated a flat hearing loss at 70 dB at 56% speech discrimination ( Figure 5 ). After a complete medical examination a diagnosis of Meniere's disease of syphilitic etiology was made. She was treated with Synthroid 0.1 mg daily and continued to have symptoms. On 2-5-70, a colleague performed a left endolymphatic subarachnoid shunt procedure. Five days later reoperation was performed to close a cerebrospinal fluid leak. Postoperatively hearing did not return in the left ear ( Figure 6 ). She was started on prednisone 5 mg four times daily and vasodilators were continued. After one month the prednisone was discontinued. She had trouble with a duodenal ulcer. Vertigo persisted and on January 26,1971 she was given prednisone again to maintain hearing in her right ear which was now fluctuating. Prednisone dosage and administration was erratic. When asked, 91% (31/34) of patients participating in a controlled clinical study stated that they would use Nasarel again.'
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Female rats receiving the highest oral dose had an increased incidence ofmammary adenocarcinoma compared tocontrol rats. An increased incidence ofthis tumor type has been reported for other corticosteroids. ness of her face. Prednisone was conti ned and she was given intravenous histamine daily for three days. The facial paralysis resolved. By January, 1973 hearing in the right ear was fluctuating and required 20 mg of prednisone daily (Figure 7) . On 3-2-73, under general anesthesia, the author performed a rightendolymphatic subarachnoid shunt procedure. The postoperative course was uneventful and hearing stabilized at the 33 dB level and at 100% speech discrimination (Figure 8 ). Hearing remained stable with 5 mg prednisone twice daily until 1976 when it became necessary for her to take 20 mg daily and to obtain a hearing aid. By 1-25-77, hearing had dropped to the 65 dB level (Figure 9 ), eight years after the onset of the disease. The patient continued to take Prednisone in a daily dosage of 15 to 25 mg to maintain her hearing. She stated that once or twice a year her hearing would drop and she would raise the dose to 5 mg five times daily for two months. She had occasional spells of vertigo. By 11-21-88 she was getting along satisfactorily with a right hearing aid and prednisone 15 mg daily (Figure 10 ), 19 years after the onset. The last follow-up examination was on 2-28-92 ( Figure II) , 23 years after the onset of symptoms. She is retired at age 69 and with her hearing aid she can communicate on a one-on-one basis in a quiet area. Comment: As in Case I, this patient did not have strict medical control early in the course of her disease. Prednisone was not always kept at optimum levels and unfortunately the first shunt operation on her left ear was not a success. The shunt operation on the right side was performed on a timely basis and the shunt has performed as expected. This patient has maintained useful hearing for 23 years and may do so indefinitely.
Impairment of Fertility

Case 3
A 48-year-old Caucasian woman was first seen on 11-2-66 with a history of episodic vertigo, tinnitus, and right hearing loss which was treated with a suboccipital right VlIIth nerve section in 1946. For the previous 12years she had fluctuating left hearing loss, tinnitus and vertigo every three months. Audiometry showed no hearing on the right side and a 42 dB low-tone hearing loss on the left (Figure 12 ). She was given Cytomel 5 meg daily and Figure  13 ) a left endolymphatic subarachnoid shunt operation was performed on February 22, 1971. There were no complications. Following the operation the FTA-abs test was found to be positive. Hearing improved and she was placed on daily prednisone which was adequate to maintain hearing in the normal range. Tinnitus was mild and she had no vertigo. One year after surgery she ceased to have tinnitus, ear pressure and vertigo. In 1975, she had three brief, mild spells of vertigo. She fell and broke a bone in her foot. In August of 1977 she began to have small spells of vertigo with left ear pressure and tinnitus. Her hearing remained the same. She increased her daily prednisone to 20 mg and obtained prompt relief of symptoms. From 1978 through 1980 she remained stable on 12.5 mg prednisone daily (Figure 14) . In January 1982 she fell and broke a vertebra in her lower back. For the next seven years she was maintained with prednisone 10 mg daily. Occasionally she raised the dose to 20 mg if she felt her hearing was poor. She developed problems with high blood pressure and emphysema. In 1989 she stopped smoking. Hearing was worse ( Figure 15 ) but she still did not use or need a hearing aid. Vasodilators were added to her treatment. She had periodic bruising of her arm. On 4-6-92 her hearing was still at an acceptable level and her prednisone dosage was at 15 mg per day. Comment: This patient has maintained truly useful hearing with a moderate pure-tone threshold level of 47 dB and 92% speech discrimination over a period of 26 years since the onset of treatment and 48 years from the onset of hearing loss in the first ear affected. This clearly Introducing the new Welch Allyn Lumi'View" Portable Binocular Microscope.
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For more information Circle 116 on Reader Service Card no PULEC represents a much slower progressive involvement than the usual case. The timely and successful accomplishment of the left endolymphatic subarachnoid shunt operation may also have contributed to the ability to use a lower dose of steroids and to long-term preservation of hearing. It is of interest to note that the right suboccipital VIIIth nerve section was performed before doctors knew about this condition. Fortunately, the procedure was successful, with no facial paralysis or other ill effect. Prompt performance of an endolymphatic subarachnoid shunt procedure in the face of rapidly progressive hearing loss in a patient's only hearing ear represents optimum treatment.
Discussion
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INDICATIONS AND USAGE
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Cimetidine (400 mgtwice daily) increased the mean Cmax and AUC of orally administered azelastine hydrochloride (4 mgtwice daily) byapproximately 65%. Ranitidine hydrochloride (150 mg twice daily) had noeffect onazelastine pharmacokinetics.
Interaction studies investigating the cardiac effects, asmeasured bythecorrected aT interval (aTc), of concomitantly administered oral azelastine hydrochloride and erythromycin or ketoconazole were conducted. Oral erythromycin (500 mgthree times daily for seven days) had noeffect onazelastine pharmacokinetics or aTc based onanalyses of serial electrocardiograms. Ketoconazole (200 mgtwice daily for 7 days) Interfered with the measurement of azelastine plasma concentrations; however, noeffects onaTc were observed. No significant pharmacokinetic interaction was observed with the coadministration of an oral 4-mg dose of azelastine hydrochloride twice daily and theophylline 300 mgor 400 mg twice daily. Geriatric Use: U.S. placebo-controlled clinical trials included 11 patients above theage of 60 years who were treated with Astelin· Nasal Spray. While thisnumber is very small and no substantial conclusions can be drawn, theadverse events in thisgroup were similar to patients under age 60years. Carcinogenesis, mutagenesis, Impairment oftertillty:Carcinogenicity studies in rats and mice with oral azelastine hydrochloride for 24months at doses upto 30 mg/kg/day and 25mg/kg/day, respectively (240 and 100 times the maximum recommended human daily intranasal dose ona mg/m 2 basis), revealed noevidence of carcinogenicity.
Azelastine hydrochloride showed nogenotoxic effects in the Ames test, DNA repair test, mouse lymphoma forward mutation assay, mouse micronucleus test, or chromosomal aberration testin ratbone marrow.
Reproduction and fertility studies in rats showed noeffects onmale or female fertility at oral doses of upto 30mg/kg/day (240 times the maximum recommended human daily intranasal dose ona mg/m 2 basis). At68.6 mg/kg/day (550 times themaximum recommended human daily intranasal dose ona mg/m 2 basis), theduration of estrous cycles was prolonged and copulatory activity and the number of pregnancies were decreased. The numbers of corpora Iutea and implantations were decreased; however, the implantation ratio was notaffected. Pregnancy Category C: Azelastine hydrochloride has been shown to beembryotoxic, fetotoxic, and teratogenic (external and skeletal abnormalities) in mice atanoral dose of 68.6 mg/kg/day (280 times the maximum recommended human daily intranasal dose ona mg/m 2 basis).
Atanoral dose of 30mg/kg/day (240 times the maximum recommended human daily intranasal dose ona mg/m 2 basis), delayed ossification (undeveloped metacarpus), and the incidence of 14th ribwere increased in rats. At68.6 mg/kg/day (550 times the maximum recommended human daily intranasal dose ona mg/m 2 basis) azelastine hydrochloride caused abortion and fetotoxic effects in rats.
The relevance to humans ofthese skeletal findings noted at only high drug exposure levels is unknown.
There are noadequate and well-controlled clinical studies in pregnant women. Astelin· Nasal Spray should be used during pregnancy only if the potential benefit justifies the potentialriskto the fetus. Nursing Mothers: It is notknown whether azelastine hydrochloride is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Astelin· Nasal Spray is administered to a nursing woman. Pediatric USQ: Safety and efficacy of Astelin· Nasal Spray in pediatric patients below theage of 12years have notbeen established. ADVERSE REACTIONS Adverse experience information for Astelin· Nasal Spray is derived from sixwell-controlled, 2-day to 8-week clinical studies which included 391 patients who received Astelin· Nasal Spray ata dose of 2 sprays pernostril twice daily. In placebo-controlled efficacy trials, the incidence of discontinuation due to adverse reactions in patients receiving Astelin· Nasal Spray was notsignificantly different from vehicle placebo (2.2% vs 2.8%, respectively).
Inthese clinical studies, adverse events that occurred statistically significantly more often in patients treated with Astelin· Nasal Spray versus vehicle placebo included bitter taste (19.7% vs0.6%). somnolence (11.5% vs 5.4%), weight increase (2.0% vs 0%), and myalgia (1.5% vs0%).
The following adverse events were reported withfrequencies 2:2% intheAstelin· Nasal Spray treatment group and more frequently than placebo in short-term ($2 days) and longterm (2-8 weeks) clinical trials. ease of other etiologies.
1. An FTA-abs test for syphilis should be performed in every case of Meniere's disease. No substitution. 2. Hearing loss may be sudden and administration of prednisone should be prompt to avoid permanent hearing loss. 3. Prednisone should be given without interruption in a divided daily dose sufficient to maintain good hearing.
An endolymphatic subarachnoid shunt operation
should be performed when hearing is not maintained with prednisone 20 mg or less per day. 5. Despite some progressive hearing loss, hearing can be maintained for more than 20 years. 8-11-80 RM. Patients who have been given steroids in large doses on an every-other-day basis generally report fluctuation based on blood levels of the steroid. For that reason it seems advisable to administer prednisone in multiple daily divided doses. Whenever hearing is not maintained at a stable level with daily prednisone of 20 mg or less an endolymphatic subarachnoid shunt operation should be performed. Under optimal conditions and with the use of both prednisone and an endolymphatic subarachnoid shunt, hearing tends to remain normal for approximately 10 years, after which it drops by 20 or 30 dB HL. It remains stable again for another 10 years by which time a hearing aid is often necessary to maintain adequate function. This study will continue and only the passage oftime will allow us to know what we might expect in the third or fourth decades of treatment. Hopefully, a method of treatment to eradicate the spirochetes of congenital syphilis will be found by scientific research.
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